InMed Pharmaceuticals (NASDAQ:INM) Posts Quarterly Earnings Results

InMed Pharmaceuticals (NASDAQ:INM) issued its earnings results on Wednesday. The company reported ($3.64) EPS for the quarter, Zacks reports. InMed Pharmaceuticals had a negative return on equity of 65.74% and a negative net margin of 137.41%.

InMed Pharmaceuticals Trading Up 3.9 %

Shares of InMed Pharmaceuticals stock traded up $0.12 during midday trading on Wednesday, reaching $3.20. 160,065 shares of the company’s stock traded hands, compared to its average volume of 1,024,570. The stock has a 50 day moving average of $4.37 and a 200-day moving average of $4.74. InMed Pharmaceuticals has a 12 month low of $2.41 and a 12 month high of $15.70. The company has a market cap of $2.30 million, a PE ratio of -0.23 and a beta of 0.19. The company has a debt-to-equity ratio of 0.08, a quick ratio of 4.22 and a current ratio of 5.07.

InMed Pharmaceuticals Company Profile

InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.